Truist lowered the firm’s price target on CVS Health (CVS) to $67 from $76 but keeps a Buy rating on the shares after its Q3 earnings miss. The firm is updating its model after the company’s Q3 results, though it remains bullish on the stock given CVS’s unique set of assets, diverse offering, robust clinical capabilities, and ongoing shift to healthcare delivery, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Dr. Oz spoke of expanding Medicare Advantage plans, says JPMorgan
- Trump names Dr. Oz as administrator of Medicare and Medicaid Services
- CVS Health appoints Sreekanth Chaguturu as president, health care delivery
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
- CVS board additions ‘should add comfort to investors,’ says Evercore ISI